IP Library › Granted Patent US 11,965,163
Granted Patent B2
US 11,965,163 · App. 17/487,664 · Granted Apr 23, 2024

HNF4a saRNA compositions and methods of use

Inventors: Hans E. Huber (Lansdale, PA); David Blakey (London, GB); Jon Voutila (London, GB); Monika Krampert (Bamberg, DE); Markus Hossbach (Kulmbach, DE)
Assignee: MiNA Therapeutics Limited
C12N15/113A61P3/06A61K31/496C12N2310/11C12N2310/14C12N2310/315C12N2310/317C12N2310/321C12N2310/322C12N2310/3515C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,965,163
App. No.
17/487,664
Granted
Apr 23, 2024
Kind
B2
Abstract

The invention relates to saRNA targeting an HNF4a transcript and therapeutic compositions comprising said saRNA. Methods of using the therapeutic compositions are also provided.

Claims (12)

1. A method of up-regulating HNF4a gene in a cell comprising administering a synthetic isolated saRNA to the cell, wherein the saRNA comprises a strand comprising the sequence of SEQ ID NO: 136.

2. The method of claim 1 , wherein the saRNA is single stranded.

3. The method of claim 1 , wherein the saRNA is double-stranded and further comprises a sense strand.

4. The method of claim 3 , wherein the sense strand comprises the sequence of SEQ ID NO: 135.

5. The method of claim 1 , wherein HNF4a P1 mRNA is up-regulated.

6. The method of claim 1 , wherein HNF4a P2 mRNA is not up-regulated.

7. The method of claim 1 , wherein the cell is a hyperproliferating cell.

8. The method of claim 7 , wherein the cell is a cancer cell.

9. The method of claim 8 , wherein the cell is a hepatocellular carcinoma (HCC) cell.

10. The method of claim 1 , wherein the cell is a hepatocyte cell.

11. The method of claim 1 , wherein HNF4a gene is up-regulated by at least 50%.

12. The method of claim 11 , wherein HNF4a gene is up-regulated by a factor of at least 2.

Assignments (5)
SECURITY INTEREST Recorded Jan 30, 2023
From: MINA (HOLDINGS) LIMITED; MINA THERAPEUTICS LIMITED; MINA ALPHA LIMITED; MINA BETA LIMITED
To: BOOTSTRAP EUROPE 3.0 S.À R.L.
Reel/Frame 062547/0070 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2022
From: HUBER, HANS E.; BLAKEY, DAVID; VOUTILA, JON
To: MINA THERAPEUTICS LIMITED
Reel/Frame 058634/0366 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2022
From: HUBER, HANS E.; BLAKEY, DAVID; VOUTILA, JON
To: MINA THERAPEUTICS LIMITED
Reel/Frame 058634/0424 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2022
From: KAMPERT, MONIKA; HOSSBACH, MARKUS
To: AXOLABS GMBH
Reel/Frame 058634/0541 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2022
From: AXOLABS GMBH
To: MINA THERAPEUTICS LIMITED
Reel/Frame 058634/0559 →
Priority Claims (1)
WO PCT/EP2017/074130 · Sep 22, 2017 · international
Continuity (5)
Division 16645012
Provisional Application 62555937 · Sep 8, 2017
Provisional Application 62555951 · Sep 8, 2017
Related Publication 20220090074A1 · Mar 24, 2022
Related Publication 20240035026A9 · Feb 1, 2024